Guggenheim Reiterates Buy on Zenas BioPharma, Maintains $55 Price Target
Zenas BioPharma, Inc.
Zenas BioPharma, Inc. ZBIO | 0.00 |
Guggenheim analyst Yatin Suneja reiterates Zenas BioPharma (NASDAQ:
ZBIO) with a Buy and maintains $55 price target.
